| Literature DB >> 34320461 |
Luchenga Adam Mucheleng'anga1, Viktor Telendiy2, Amos Hamukale3, Aaron Lunda Shibemba4, Alimuddin Zumla5, Cordelia Maria Himwaze6.
Abstract
BACKGROUND: Data from Africa regarding sudden and unexpected COVID-19 community deaths and underlying pathological, demographic, and co-morbidity features require definition.Entities:
Keywords: Africa; COVID-19; Forensic; Lusaka-Zambia; SARS-CoV-2; community deaths; post-mortem examination
Mesh:
Year: 2021 PMID: 34320461 PMCID: PMC8255190 DOI: 10.1016/j.ijid.2021.07.001
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Demographic Characteristics
Table 1. Demographic characteristics, Symptoms, and Co-morbidities
| Variable | Community Deaths (n=21) N(%) |
|---|---|
| Sex | |
| Male | 14 (66.2) |
| Female | 7 (33.3) |
| Mean Age ± SD (Range)years | 40 ± 12.3 (20-73) |
| 15-25 | 2 (9.5) |
| 26-35 | 4 (19.1) |
| 36-45 | 10 (47.6) |
| 46-55 | 2 (9.5) |
| 56-65 | 2 (9.5) |
| 66-75 | 1 (4.8) |
N (%): number of cases (percentage)
Symptoms and co-morbidities
| Variable | Community Deaths (n=21) N(%) |
|---|---|
| SYMPTOMS | |
| Difficulty breathing | 7(33.3) |
| Cough | 6(28.6) |
| Fever | 1(4.8) |
| Headache | 3(14.3) |
| General Body Weakness | 3(14.3) |
| Chest Pains | 5(23.8) |
| Vomiting | 1(4.8) |
| Diarrhea | 1(4.8) |
| Joint Pains | 1(4.8) |
| Sneezing | 1(4.8) |
| Duration of symptoms in Days- Median (IQR) | 1(0-2) |
| CO-MORBIDITIES | |
| HIV positive | 1(4.8) |
| Hypertension | 3(14.3) |
| Tuberculosis | 1(4.8) |
| Diabetes | 1(4.8) |
| Obesity | 3(14.3) |
| Pregnancy | 1(4.8) |
| Pneumonia | 1(4.8) |
| Drug and alcohol use | 1(4.8) |
Autopsy findings and causes of death
| Autopsy findings | Community Deaths (n=21) N(%) |
|---|---|
| Diffuse Alveolar Damage | 17(80.9) |
| Saddle Emboli | 8(38.1) |
| Shower Emboli | 8(38.1) |
| Pneumonia | 3(14.3) |
| Granular kidneys | 2(9.5) |
| Deep Venous Thrombosis | 3(14.3) |
| Tuberculosis | 2(9.5) |
| Autopsy Causes of death | |
| Diffuse Alveolar Damage | 3 (14.3) |
| Pneumonia | 2 (9.5) |
| Pulmonary Thromboembolism | 16 (76.2) |
Figure 1Gross Pathology Findings. (A): Kidneys: A case of chronic hypertension depicting kidneys with granular surfaces. (B): Lung: Pulmonary thromboembolism depicting a thrombus in the pulmonary vessels (white arrowhead). (C): Lung: Pneumonia depicting grey hepatization (D): Lung: Caseating lesions in a case of Pulmonary tuberculosis
Figure 2Microscopic pathology findings. (A): Kidney micrograph (X 40): A case of chronic hypertension depicting a hyalinized artery (white arrowhead). (B): Lung micrograph (X 20): A case of pulmonary thromboembolism depicting a thrombus in the pulmonary vessels (white arrowhead). (C): Lung micrograph (X 20): A case of tuberculosis depicting granulomatous inflammation (white arrowheads). (D): Lung micrograph (X 40): A case showing Diffuse Alveolar Damage. The hyaline membranes (white arrowheads) are observed to line the alveolar walls. (E): Lung micrograph (X 40): A case showing Organizing Pneumonia (white arrowhead).(F): Lung micrograph (X 20): A case of Acute Pneumonia depicting neutrophils in the alveolar spaces (white arrowheads).
Summary of 21 Community Deaths Post-Mortem Examinations
| Case # | Sex/Age | Symptoms | Duration of illness | Co-morbidities | Gross and microscopic findings | Cause of death |
|---|---|---|---|---|---|---|
| 1 | M/58 | Cough and Difficulties breathing | 1 day | Diabetes and Hypertension | Heavy lungs (>1000 g each), shower thromboemboli, iliac artery thromboemboli, thromboemboli in the heart, granular kidneys, and DAD | Pulmonary thromboembolism due to COVID-19 |
| 2 | M/32 | Headache and Diarrhea | 1 day | None | Heavy lungs (>1000 g each), saddle thromboemboli, and DAD | Pulmonary thromboembolism due to COVID-19 |
| 3 | M/37 | Chest pains and Difficulties breathing | 5 hours | None | Saddle thromboemboli | Pulmonary thromboembolism due to COVID-19 |
| 4 | M/51 | Chest pains and difficulties breathing | 7 hours | None | Saddle thromboemboli | Pulmonary thromboembolism due to COVID-19 |
| 5 | M/20 | Painful legs and Difficulties breathing | 1 day | None | Heavy lungs (>1000 g each), saddle thromboemboli, and DAD | Pulmonary thromboembolism due to COVID-19 |
| 6 | F/38 | Cough and Difficulties breathing | 2 days | HIV and Disseminated Tuberculosis | Disseminated tuberculosis, heavy lungs (>1000 g each), shower thromboemboli, and DAD | Pulmonary thromboembolism due to COVID-19 |
| 7 | F/39 | Chest pains | 1 hour | None | Saddle thromboemboli | Pulmonary thromboembolism due to COVID-19 |
| 8 | M/42 | Fever, Cough, Joint pains, and Headache | 14 hours | Pneumonia | Shower thromboemboli, heavy lungs (>1000 g each), consolidation of lungs and neutrophils in alveolar spaces, and DAD | Pulmonary thromboembolism due to COVID-19 |
| 9 | M/38 | Unknown | 1 hour | None | Heavy lungs (>1000 g each), saddle thromboemboli | Pulmonary thromboembolism due to COVID-19 |
| 10 | F/27 | General body weakness | 7 days | Pulmonary tuberculosis | Shower thromboemboli, pulmonary tuberculosis, and DAD | Pulmonary thromboembolism due to COVID-19 |
| 11 | M/38 | Cough Difficulties breathing | 5 days | None | Shower thromboemboli and DAD | Pulmonary thromboembolism due to COVID-19 |
| 12 | M/44 | Cough Difficulties breathing | 1 day | Hypertension Obesity | Heavy lungs (>1000 g each), granular kidneys, and DAD | Diffuse Alveolar Damage due to COVID-19 |
| 13 | F/40 | Self-isolating, Sneezing, and coughing | 21 hours | Obese | Shower thromboemboli, heavy lungs (>1000 g each), and DAD | Pulmonary thromboembolism due to COVID-19 |
| 14 | F/59 | General body weakness | 1 day | Obese | Heavy lungs (>1000 g each) and DAD | Diffuse Alveolar Damage due to COVID-19 |
| 15 | F/43 | Chest pains in pregnancy | 1 day | None | Shower thromboemboli, heavy lungs (>1000 g each), deep venous thrombosis, and DAD | Pulmonary thromboembolism due to Deep Vein Thrombosis due to COVID-19 |
| 16 | M/32 | General body weakness | 1 day | None | Heavy lungs (>1000 g each), consolidation of lungs and neutrophils in alveolar spaces, and DAD | Pneumonia due to COVID-19 |
| 17 | M/28 | Vomiting | 2 days | Alcoholism Drug abuse | Shower thromboemboli, heavy lungs (>1000 g each), deep venous thrombosis, and DAD | Pulmonary thromboembolism due to Deep Vein Thrombosis due to COVID-19 |
| 18 | M/73 | Chest pains | 1 day | Hypertension | Shower thromboemboli, heavy lungs (>1000 g each), and DAD | Diffuse Alveolar Damage due to COVID-19 |
| 19 | M/43 | None | < 1 day | None | Shower thromboemboli, Heavy lungs (>1000 g each), and DAD | Pulmonary thromboembolism due to COVID-19 |
| 20 | 46/M | Headache | 1 day | None | Heavy lungs (>1000 g each), consolidation of lungs and neutrophils in alveolar spaces, and DAD | Pneumonia due to COVID-19 |
| 21 | F/25 | Convulsions | 5 hours | None | Deep Vein Thrombosis, heavy lungs (>1000 g each), saddle thromboemboli, brain (1250 g) unremarkable, and DAD | Pulmonary thromboembolism due to Deep Vein Thrombosis due to COVID-19 |
Comparison of Community versus Hospital Autopsy findings and causes of death in Lusaka, Zambia
| Overall Deaths (N=50) N(%) | Community Deaths (n=21) N(%) | Hospital Deaths | Statistic (p-value) N(%) | |
|---|---|---|---|---|
| Autopsy Findings | ||||
| Diffuse Alveolar Damage | 29(58.0) | 17(80.9) | 12(41.4) | 7.830 (0.005)* |
| Saddle Emboli | 14(28.0) | 8(38.1) | 6(20.7) | 1.830 (0.176) |
| Shower Emboli | 12(24.0) | 8(38.1) | 4(13.8) | 3.944 (0.047)* |
| Pneumonia | 12(24.0) | 3(14.3) | 9(31) | 1.873 (0.171) |
| Granular kidneys | 7(14.0) | 2(9.5) | 5(17.2) | 0.603 (0.684) |
| Deep Venous Thrombosis | 6(12.0) | 3(14.3) | 3(10.3) | 0.179 (0.686) |
| Disseminated Thrombi | 4(8.0) | 0(0.0) | 4(13.8) | 3.148 (0.129) |
| Tuberculosis | 3(6.0) | 2(9.5) | 1(3.4) | 0.739 (0.565) |
| Anemia | 1(2.0) | 0(0.0) | 1(3.4) | 0.739 (0.999) |
| Kaposi Sarcoma | 1(2.0) | 0(0.0) | 1(3.4) | 0.739 (0.999) |
| Colorectal adenocarcinoma | 1(2.0) | 0(0.0) | 1(3.4) | 0.739 (0.999) |
| Cause(s) of Death | ||||
| Diffuse Alveolar Damage | 12 (24.0) | 3 (14.3) | 9 (31.0) | 1.873 (0.171) |
| Pneumonia | 9 (18.0) | 2 (9.5) | 7 (24.2) | 1.762 (0.271) |
| Pulmonary Thromboembolism | 29 (58.0) | 16 (76.2) | 13 (44.8) | 4.918 (0.027)* |
Fisher's exact test; p<0.05
Himaze C et al, 20216